Teva Pharmaceutical Industries (TEVA) said Monday the US Food and Drug Administration has accepted its US affiliate Teva Pharmaceuticals' supplemental biologics license application for AJOVY to expand the indication to include the prevention of episodic migraine in certain pediatric patients.
The application was based on results from the phase 3 SPACE trial which demonstrated statistically significant improvements in reducing monthly migraine days and monthly headache days using AJOVY compared to a placebo, the company said.
Teva's share price rose more than 5% in recent premarket activity.
Price: 14.54, Change: +0.74, Percent Change: +5.36
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。